Related Experiment Videos
A novel PNET cell line with melanotic differentiation
S Moriuchi1, K Shimizu, Y Miyao
1Department of Neurosurgery, Center for Adult Diseases, Osaka, Japan.
Anticancer Research
|March 1, 1996
Summary
A new cell line, ONS-99, was developed from a human melanotic neuroectodermal tumor of infancy (MNTI). This primitive neuroectodermal tumor (PNET) line shows melanotic differentiation, offering a unique research model.
Area of Science:
- Oncology
- Cell Biology
- Developmental Biology
Background:
- Primitive neuroectodermal tumors (PNETs) are aggressive neoplasms.
- Establishing cell lines with specific differentiation is crucial for PNET research.
- Melanotic neuroectodermal tumor of infancy (MNTI) is a rare pediatric tumor.
Purpose of the Study:
- To establish and characterize a novel cell line from a human MNTI.
- To investigate the differentiation potential of the established cell line.
- To provide a unique in vitro and in vivo model for PNET research.
Main Methods:
- Cell culture and establishment of the ONS-99 cell line from MNTI.
- In vitro characterization including morphology and immunophenotype (NSE, HMB-45, N-myc).
- In vivo transplantation studies in immunodeficient mice (BALB/c-nu/nu).
Main Results:
- The ONS-99 cell line was successfully established and characterized as polygonal adherent cells.
- Immunohistochemistry confirmed positivity for NSE, HMB-45, and N-myc, indicating melanotic differentiation.
- Electron microscopy revealed intermediate filaments and tight intercellular junctions, consistent with PNET characteristics.
Conclusions:
- The ONS-99 cell line represents the first established PNET cell line with documented melanotic differentiation.
- This unique cell line serves as a valuable model for studying MNTI and PNET biology.
- Further research with ONS-99 can elucidate PNET pathogenesis and therapeutic strategies.